Skip to main content
SpringerLink
Log in

Serum lipids and apolipoproteins in women with breast masses

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Background: Human mammary tissue metabolizes lipids from plasma, a process affected by female gonadal hormones. Both benign and malignant proliferation of breast tissue in women have been associated with changes in plasma lipid and lipoprotein levels.Methods: One hundred consecutive women with breast masses (50 malignant, 50 benign) had diagnostic biopsies followed by axillary node dissection in those with cancer. Fasting serum samples were taken just prior to biopsy and analyzed for lipid fatty acid and lipoprotein levels. Malignant breast tissue was analyzed for hormone receptor binding.Results: Low-density lipoprotein (LDL) components (total cholesterol, LDL-cholesterol, apolipoprotein B) were increased, but not significantly, in cancer patients compared to those with benign masses. Decreased levels of LDL-associated components were found in women with cancer recurrence by 3 years. Three apolipoproteins of high-density lipoprotein (apolipoprotein A-I, apolipoprotein A-II, apolipoprotein D) were more affected by the presence of breast masses than the lipids were. Fibrocystic disease, type of hormone binding, and recurrence within 3 years were significantly related to apolipoprotein changes, especially apolipoprotein D levels with hormone receptor binding and the apolipoprotein A-I/apolipoprotein B ratio with breast cancer recurrence.Conclusions: Prior to diagnostic biopsy, serum lipid and apolipoprotein components of low-density lipoproteins were increased in women with fibrocystic disease and early stage cancer but decreased in women with early recurrence. However, apolipoprotein A-I, apolipoprotein A-II, and apolipoprotein D, of the high-density lipoproteins, were more affected than serum lipids. The ratio of apolipoprotein A-I to apolipoprotein B serum levels at time of biopsy was the best predictor of cancer recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fossel ET, Carr JM, McDonagh J: Detection of malignant tumors by water-suppressed proton nuclear magnetic resonance spectroscopy of plasma. N Eng J Med 315: 1369–1376, 1986

    Google Scholar 

  2. Moreno A, Escrich E, Prats M, Benito N, Alonso J, Arus C: Study of the ability of proton nuclear magnetic resonance spectroscopy of human plasma to differentiate between controls and breast cancer patients. Oncology 50: 110–115, 1993

    Google Scholar 

  3. Holmberg L, Jakobsson U, Bergland A, Adami HO: Failure to detect early breast cancer usingin vitro nuclear magnetic resonance spectroscopy of plasma. Br J Cancer 68: 389–392, 1993

    Google Scholar 

  4. Rose G, Shipley MJ: Plasma lipids and mortality: A source of error. Lancet i: 523–526, 1980

    Google Scholar 

  5. Cambien F, Ducimetiere P, Richard J: Total serum cholesterol and cancer mortality in a middle-aged male population. Am J Epidemiol 112: 388–394, 1980

    Google Scholar 

  6. Garcia-Palmieri MR, Sorlie PD, Costas R Jr, Havlik RJ: An apparent inverse relationship between serum cholesterol and cancer mortality in Puerto Rico. Am J Epidemiol 114: 29–40, 1981

    Google Scholar 

  7. Spiegel RJ, Schaefer EJ, Magrath IT, Edwards BK: Plasma lipid alterations in leukemia and lymphoma. Am J Med 72: 775–782, 1982

    Google Scholar 

  8. Budd D, Ginsberg H: Hypocholesterolemia and acute myelogenous leukemia: Association between disease activity and plasma low-density lipoprotein cholesterol concentrations. Cancer 58: 1361–1365, 1986

    Google Scholar 

  9. Muller CP, Wagner AU, Maucher C, Steinke B: Hypocholesterolemia, an unfavorable feature of prognostic value in chronic myeloid leukemia. Eur J Haematol 43: 235–239, 1989

    Google Scholar 

  10. Muller CP, Trilling B, Ing D, Steinke B: The prognostic significance of total serum cholesterol in patients with Hodgkins disease. Cancer 69: 1042–1046, 1992

    Google Scholar 

  11. Dyer AR, Stamler J, Paul O, Shekelle RB, Schoenberger JA, Berkson DM, Lepper M, Collette P, Shekelle S, Lindberg HA: Serum cholesterol and risk of death from cancer and other causes in three Chicago epidemiological studies. J Chron Dis 34: 249–260, 1981

    Google Scholar 

  12. Kritchevsky SB, Kritchevsky D: Serum cholesterol and cancer risk: An epidemiologic perspective. Annu Rev Nutr 12: 391–416, 1992

    Google Scholar 

  13. Warnick GR: Enzymatic methods for quantitation of lipoprotein lipids. Methods Enzymol 129: 101–123, 1986

    Google Scholar 

  14. Alaupovic P, McConathy WJ, Fesmire J, Tavella M, Bard JM: Profiles of apolipoproteins and apolipoprotein B-containing lipoprotein particles in dyslipoproteinemias. Clin Chem 48: B13-B27, 1988

    Google Scholar 

  15. Ye S-Q, Keeling J, Stein O, Stein Y, McConathy WJ: Tissue distribution of3H-cholesteryl linoleyl ether-labeled human Lp(a) in different rat organs. Biochem Biophys Acta 963: 534–540, 1988

    Google Scholar 

  16. McConathy WJ, Blackett PR, Kling OR: Studies on serum apolipoproteins and lipids in amniotic fluid and neonatal urine. Clin Chem Acta 111: 153–162, 1981

    Google Scholar 

  17. The Lipid Research Clinics Program Epidemiology Committee. Plasma lipid distributions in selected North American populations: The Lipid Research Clinics Program Prevalence Study. Circulation 60: 427–439, 1979

    Google Scholar 

  18. Heiss G, Tamir I, Davis CA, Tyroler HA, Rifkind BM, Schonfeld G, Jacobs D, Frantz ID: Lipoprotein-cholesterol distributions in selected North American populations: The Lipid Research Clinics Program Prevalence Study. Circulation 61: 301–315, 1980

    Google Scholar 

  19. Dupont WD, Page DL: Breast cancer risk associated with proliferative disease, age at first birth, and a family history of breast cancer. Am J Epidemiol 125: 769–779, 1987

    Google Scholar 

  20. Saftlas AF, Azklo M: Mammographic parenchymal patterns and breast cancer risk. Epidemiol Rev 9: 146–174, 1987

    Google Scholar 

  21. London SJ, Connolly JL, Schnitt SJ, Colditz GA: A prospective study of benign breast disease and the risk of breast cancer. JAMA 267: 941–944, 1992

    Google Scholar 

  22. Boyd NF, McGuire V, Fishell E, Kuriov V, Lockwood G, Tritchler D: Plasma lipids in premenopausal women with mammographic dysplasia. Brit J Cancer 59: 766–771, 1989

    Google Scholar 

  23. Kumar K, Sachdanandam P, Arivazhagan R: Studies on the changes in plasma lipids and lipoproteins in patients with benign and malignant breast cancer. Biochem Int 23: 581–589, 1991

    Google Scholar 

  24. Bani IA, Williams CM, Boulter PS, Dickerson JWT: Plasma lipids and prolactin in patients with breast cancer. Brit J Cancer 54: 439–446, 1986

    Google Scholar 

  25. Potischman N, McCulloch CE, Byers T, Houghton L, Nemeto T, Graham S, Campbell TC: Associations between breast cancer, plasma triglycerides and cholesterol. Nutr Cancer 15: 205–215, 1991

    Google Scholar 

  26. Knapp ML, Al-Sheibani S, Riches PG: Alterations in serum lipids in breast cancer: Effects of disease activity, treatment, and hormonal factors. Clin Chem 37: 2093–2101, 1991

    Google Scholar 

  27. Chajes V, Hacene K, Lanson M, Body G, Bougnoux P: Fatty acid composition of aggressive breast cancer. Breast Cancer Res Treat 19: 213A, 1991

    Google Scholar 

  28. Schuler LA, Langenberg KK, Gwynne JT, Strauss JF: High density lipoprotein utilization by dispersed rat luteal cells. Biochim Biophys Acta 664: 583–601, 1981

    Google Scholar 

  29. Schreiber JR, Edelstein C, Scanu AM:In vitro effect of high density lipoproteins with varying ratios of ApoA-I to ApoA-II on steroidogenesis by rat ovary granulosa cells. In: Strauss JF, Memon KMJ (eds) Lipoprotein and Cholesterol Metabolism in Steroidogenic Tissues. George F. Stickley Company, Philadelphia, 131–134, 1985

    Google Scholar 

  30. Pearlman WH, Peng LH, Mazoujian G, Haagensen DE, Wells SA, Kister SJ: A specific progesterone-binding component of human breast cyst fluid. Its isolation and characterization. J Endocrinol 75: 19–20, 1977

    Google Scholar 

  31. Mazoujian G, Haagensen DE: The immunopathology of gross cystic disease fluid proteins. Ann NY Acad Sci 586: 188–197, 1990

    Google Scholar 

  32. Balbin M, Freije JMP, Fueyo A, Sanches LM, Lopez-Otin C: Apolipoprotein D is the major protein component in cyst fluid from women with human breast gross cyst disease. Biochem J 271: 803–807, 1990

    Google Scholar 

Download references

Author information

Author notes

  1. Walter J. McConathy

    Present address: Dept. of Medicine, University of North Texas Health Science Center, Fort Worth, Texas, USA

Authors and Affiliations

  1. Oklahoma Medical Research Foundation, 5300 N. Grand Blvd., Suite 205, 73112, Oklahoma City, Oklahoma, USA

    Daniel M. Lane & Walter J. McConathy

  2. Baptist Medical Center of Oklahoma, 5300 N. Grand Blvd., Suite 205, 73112, Oklahoma City, Oklahoma, USA

    Daniel M. Lane & Karl K. Boatman

Authors
  1. Daniel M. Lane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karl K. Boatman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Walter J. McConathy
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lane, D.M., Boatman, K.K. & McConathy, W.J. Serum lipids and apolipoproteins in women with breast masses. Breast Cancer Res Tr 34, 161–169 (1995). https://doi.org/10.1007/BF00665788

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00665788

Key words

Search

Navigation